Logo.png
Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy
28 mars 2023 08h45 HE | Morphogenesis Inc.
Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to checkpoint inhibitors and...
Steadman Philippon R
Steadman Philippon Research Institute Receives Third NIH Grant Vail, Colorado, Aug. 22, 2019 (GLOBE NEWSWIRE) -- The National Institutes of Health (NIH) awarded Steadman Philippon Research Institute (SPRI) a grant to study muscle-derived stem cells (MDSCs)...